Investigation of drugs and underlying diseases affecting the development of HMG-CoA reductase inhibitor-induced rhabdomyolysis using the FDA Adverse Event Reporting System

○Shinya Fukumoto

[30P-am363S] Investigation of drugs and underlying diseases affecting the development of HMG-CoA reductase inhibitor-induced rhabdomyolysis using the FDA Adverse Event Reporting System

○Shinya Fukumoto¹, Keiko Ogawa¹, Chieri Fujino¹, Aika Tagami¹, Ayumi Noda¹, Rikuto Kawamura¹, Toshiya Katsura¹, Rumiko Hosoki¹ (1. Pharm. Sci., Ritsueikan Univ.)

Enter the password to view the abstracts.
The password will be emailed to those who have completed the registration.

Presentation information

[30P-am] Social Pharmacy

[30P-am363S] Investigation of drugs and underlying diseases affecting the development of HMG-CoA reductase inhibitor-induced rhabdomyolysis using the FDA Adverse Event Reporting System

Password